“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Phase

Division (Location)

Study ID

NCT#

Brief Description
“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.